Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
YD Life Science Proves Efficacy Of Diabetic Treatment
Details : Post-dose vision in all YD-312 dose groups compared with pre-dose was statistically significant, visual acuity was maintained, or the treatment efficiency improved significantly compared to the placebo group, the official noted.
Product Name : YD-312
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2020
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable